Although p16 may interact with both CDK4 and CDK6, p16 inhibition of CDK4 may be more important than CDK6 given that some melanoma-prone families have inherited activating mutations in CDK4, while none with activating CDK6 mutations have been described [6]. Here, CDKN2A is linked to melanoma.